Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

NCT03136185 is registered in ClinicalTrials.gov with Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) as lead sponsor.

NCT NCT03136185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03136185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Lead sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase
Phase 1/2
Overall status
Completed
Start date
July 18, 2017
Completion date
March 8, 2022
Enrollment
90 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post-essential thrombocythemia myelofibrosis (pet-mf), post-polycythemia vera myelofibrosis (ppv-mf), primary myelofibrosis (pmf)